NeuBase Therapeutics, Inc. (NBSE) Social Stream



NeuBase Therapeutics, Inc. (NBSE): $0.81

-0.21 (-20.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NBSE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 427

in industry

NeuBase Therapeutics Inc (NBSE) Price Targets From Analysts

Use the tables below to see what analysts covering NeuBase Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-09-13 2 $18 $15 $16.666 $1.93 763.52%
2022-02-16 3 $18 $15 $16.666 $1.93 763.52%

The Trend in the Analyst Price Target


NBSE's average price target has moved down $0.33 over the prior 48 weeks.

Over the past 46 weeks, NBSE's average upside potential has been 317.57%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-05 5 18 15 16.500 5.29 211.91%
2021-06-13 5 18 15 16.500 5.17 219.15%
2021-07-17 5 18 15 16.500 3.90 323.08%
2021-08-05 5 18 15 16.500 3.56 363.48%
2022-02-16 3 18 15 16.666 1.45 1049.38%

NBSE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 3 0 0 0 0 3

The Trend in the Broker Recommendations


NBSE's average broker recommendation rating improved by 0.75 over the prior 123 days.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for NBSE as an investment opportunity.

  • NBSE has a higher upside potential (average analyst target price relative to current price) than 294.69% of all US stocks.
  • In the context of all US stocks, NeuBase Therapeutics Inc's number of analysts covering the stock is higher than 15.78% of them.
  • In terms of how NeuBase Therapeutics Inc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than 60.49% of that group.
  • NeuBase Therapeutics Inc's average analyst price target is higher than 82.29% of Healthcare stocks.

Stocks similar to NeuBase Therapeutics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are MTCR, MNPR, and MDNA.

What is the outlook for NBSE? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.575 seconds.